Grifols Reports Strong Biopharma Growth Driven by Gamunex and Yimmugo
Grifols, S.A. (NASDAQ:GRFS) reported Q1 revenue of €1.7 billion with a 3.3% increase in constant currency year-over-year, driven primarily by its Biopharma segment growth supported by demand for immunoglobulin products and the rollout of Yimmugo in the U.S.
Tickers: $GRFS
Topics: biopharma immunoglobulin demand product rollout revenue growth